title: Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.
abstract: In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively.
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
mesh_terms: D000577:Amides / Q000627:therapeutic use*; D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D005650:Fumarates / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D005650:Fumarates; D014665:Vasodilator Agents; D017311:Amlodipine; C446481:aliskiren